Safety and immunogenicity of a synthetic nanoparticle-based, T cell priming peptide vaccine against dengue in healthy adults in Switzerland: a double-blind, randomized, vehicle-controlled, phase 1 study.
Journal Information
Full Title: EBioMedicine
Abbreviation: EBioMedicine
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Subject Category: Genetics, Medical
Available in Europe PMC: Yes
Available in PMC: Yes
PDF Available: No
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"Declaration of interests All authors and the PV CRO Qvigilance declare no competing interests."
"This work was sponsored and funded by Emergex Vaccines Holding Limited. We thank the sponsor (Athanasios Papadopoulos, Lorraine Mumtaz, Thomas Rademacher, Firdos Sayed, MaiLee Tansley) for their support in the different steps of the trial and Qvigilance for the safety data management."
"This study was approved by the local ethics committee (Commission cantonale (Vaud) d'éthique de la recherche sur l'être humain, 2020-02258) and by Swiss regulatory authorities (Swissmedic, 2021DR1042). All participants provided written informed consent. This study is registered at ClinicalTrials.gov, NCT04935801."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025